RecruitingRecruiting
An Early Feasibility Study of a Robotically Implanted Brain-Computer Interface for Neural Control of External Devices in Spinal Cord Injury, Amyotrophic Lateral Sclerosis, and Chronic Ischemic Stroke
NCT07929792 · Neuralink Corp
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
About this study
The purpose of this study is to evaluate the safety and preliminary effectiveness of the N1 System, a fully implanted brain-computer interface placed in the motor cortex with the R1 Robot. The study builds on knowledge gained in a previous clinical investigation of this system. It enrolls adults with severe upper-limb impairment from spinal cord injury, amyotrophic lateral sclerosis (ALS), or chronic ischemic stroke. Participants use neural signals recorded by the N1 Implant to control a computer cursor or virtual keyboard. The study will describe serious adverse device effects and will assess digital daily activities, computer-control performance, independent use of the system, and participant-, clinician-, and caregiver-reported outcomes. Up to 10 participants will be enrolled at up to five sites in the United States and followed for about 2 years after implantation, or about 3 years if they choose extended follow-up. There is no comparison group; each participant's results are compared with their own baseline.
Eligibility criteria
Inclusion Criteria:
Adults with a diagnosis of ALS, spinal cord injury or chronic ischemic stroke who have severe weakness in the arms and hands that limits independent use of a computer or phone.
* Stable medical, physical and psychological condition
* Ability to communicate verbally or with a communication aid
* A caregiver available when daily support is needed
Exclusion Criteria:
* Morbid obesity (Body Mass Index \> 40)
* History of poorly controlled seizures or epilepsy
* Requires magnetic resonance imaging (MRI) for any ongoing medical conditions
* Prior brain implant or active implanted medical device
* Psychiatric disorder or cognitive impairment
* Recent heart attack or cardiac arrest
* Blood thinners that cannot be paused for surgery
* Brain MRI or CT demonstrating hemorrhage, tumor, or distorted or adverse anatomy
* Any condition which, in the opinion of the Investigator, would compromise your ability to safely participate in the study or undergo the implantation procedure
Study design
Enrollment target: 10 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-11
Estimated completion: 2031-11
Last updated: 2026-11-12
Interventions
Device: N1 ImplantDevice: R1 Robot
Primary outcomes
- • Serious adverse device effects (SADEs) (From surgical implantation day ("Day 0") through the 90-day follow-up visit.)
Sponsor
Neuralink Corp · industry
Contacts & investigators
ContactNeuralink Clinical Team · contact · clinical-team-ct@neuralink.com · (877) 398-4465
All locations (1)
University of MiamiRecruiting
Miami, Florida, United States